CN102458463B - 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法 - Google Patents

针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法 Download PDF

Info

Publication number
CN102458463B
CN102458463B CN201080033258.1A CN201080033258A CN102458463B CN 102458463 B CN102458463 B CN 102458463B CN 201080033258 A CN201080033258 A CN 201080033258A CN 102458463 B CN102458463 B CN 102458463B
Authority
CN
China
Prior art keywords
hsv
seq
polypeptide
bacterin preparation
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080033258.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102458463A (zh
Inventor
D·龙
J·弗利切纳
M·斯科贝恩
G·R·西伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genocea Biosciences Inc
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Priority to CN201611104488.8A priority Critical patent/CN106924728B/zh
Publication of CN102458463A publication Critical patent/CN102458463A/zh
Application granted granted Critical
Publication of CN102458463B publication Critical patent/CN102458463B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201080033258.1A 2009-05-22 2010-05-24 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法 Expired - Fee Related CN102458463B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611104488.8A CN106924728B (zh) 2009-05-22 2010-05-24 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US61/180,784 2009-05-22
US23562809P 2009-08-20 2009-08-20
US61/235,628 2009-08-20
US24058709P 2009-09-08 2009-09-08
US24062609P 2009-09-08 2009-09-08
US61/240,626 2009-09-08
US61/240,587 2009-09-08
US30591810P 2010-02-18 2010-02-18
US61/305,918 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611104488.8A Division CN106924728B (zh) 2009-05-22 2010-05-24 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法

Publications (2)

Publication Number Publication Date
CN102458463A CN102458463A (zh) 2012-05-16
CN102458463B true CN102458463B (zh) 2017-01-18

Family

ID=43126545

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080033258.1A Expired - Fee Related CN102458463B (zh) 2009-05-22 2010-05-24 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
CN201611104488.8A Expired - Fee Related CN106924728B (zh) 2009-05-22 2010-05-24 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611104488.8A Expired - Fee Related CN106924728B (zh) 2009-05-22 2010-05-24 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法

Country Status (17)

Country Link
US (3) US8617564B2 (enExample)
EP (3) EP2432504B1 (enExample)
JP (2) JP5771605B2 (enExample)
KR (1) KR101746872B1 (enExample)
CN (2) CN102458463B (enExample)
AU (1) AU2010249330B2 (enExample)
BR (1) BRPI1012811A2 (enExample)
CA (1) CA2797937C (enExample)
ES (1) ES2732815T3 (enExample)
IL (1) IL216508A (enExample)
MX (1) MX2011012347A (enExample)
MY (1) MY159500A (enExample)
NZ (1) NZ597182A (enExample)
RU (1) RU2585961C9 (enExample)
SG (1) SG176207A1 (enExample)
WO (2) WO2010135747A1 (enExample)
ZA (1) ZA201109444B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
EP2643014A4 (en) * 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
JP6199878B2 (ja) * 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EA034351B1 (ru) * 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
US20140093537A1 (en) * 2012-09-30 2014-04-03 Nanobio Corporation Immunogenic compositions comprising nanoemulsion and methods of administering the same
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
WO2015134368A2 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine Of Yeshiva University Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
RS62747B1 (sr) 2016-02-01 2022-01-31 Simplexia Ab Skraćeni glikoprotein g herpes simpleks virusa 2
HUE049237T2 (hu) * 2016-04-08 2020-09-28 Krystal Biotech Inc Készítmények a bõr sérülései, rendellenességei és betegségei kezelési eljárásaiban történõ alkalmazásra
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
EP3615060A4 (en) 2017-04-26 2021-06-09 Merck Sharp & Dohme Corp. HSV ANTIGEN PEPTIDS AND HSV PROTEIN VACCINES
EP4242223A3 (en) * 2017-08-17 2024-03-13 The Trustees of The University of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
CN113747925B (zh) 2019-03-21 2024-10-15 隆萨销售股份公司 胞外囊泡缀合物及其用途
PH12021552223A1 (en) 2019-03-21 2022-05-30 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN117412986A (zh) 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体
IL311239A (en) 2021-09-09 2024-05-01 Affinivax Inc Multivalent pneumococcal vaccines

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) * 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
ATE179614T1 (de) * 1990-08-02 1999-05-15 Chiron Corp Herpes simplex virus vp16 impfstoffe
DK31991D0 (da) * 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994029456A2 (en) 1993-06-08 1994-12-22 Abbott Laboratories Herpes simplex virus type-2 protease
CN1133594A (zh) 1993-08-20 1996-10-16 史密丝克莱恩比彻姆公司 单纯性疱疹病毒-2ul26基因，衣壳蛋白，免疫测定和蛋白酶抑制剂
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) * 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
KR100564268B1 (ko) * 1996-10-23 2006-03-27 와이어쓰 백신
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
CA2270282A1 (en) 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
WO1998055145A1 (en) 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) * 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
TR200002608T2 (tr) * 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
CN1348463A (zh) * 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
EP1185662B1 (fr) * 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CN1376201A (zh) * 1999-09-30 2002-10-23 华盛顿大学 免疫学上重要的单纯疱疹病毒抗原
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
ES2258987T3 (es) 1999-12-17 2006-09-16 Wyeth Holdings Corporation Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple.
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
AU2001273128C1 (en) 2000-06-29 2006-09-21 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
DE60131975T2 (de) * 2000-07-27 2008-12-18 The Trustees Of The University Of Pennsylvania Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20020094337A1 (en) * 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
US7314624B2 (en) 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
ATE488249T1 (de) * 2001-07-31 2010-12-15 Univ Washington Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
ATE414176T1 (de) * 2002-07-18 2008-11-15 Univ Washington Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
US7267940B2 (en) * 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
JP5492418B2 (ja) * 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
EP2001516A4 (en) 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
EP2521786B1 (en) * 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
AU2007292905B2 (en) * 2006-09-08 2013-05-23 The Trustees Of The University Of Pennsyvania HSV-1 and HSV-2 vaccines and methods of use thereof
WO2008140478A2 (en) 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
AU2008274887B2 (en) 2007-07-06 2013-10-31 The University Of Sydney Epitopes of herpes simplex virus
US20090291095A1 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion adjuvants
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
EP3413049B1 (en) 2008-07-01 2020-10-28 Genocea Biosciences Inc. Antigen screening system
CA2781805A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010103017A2 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
DK2544693T3 (en) 2010-03-09 2017-12-04 Biomedical Res Models Inc Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2
WO2012054755A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Also Published As

Publication number Publication date
EP2432504A4 (en) 2013-07-31
EP3756684A1 (en) 2020-12-30
JP5771605B2 (ja) 2015-09-02
EP2432504A1 (en) 2012-03-28
JP2015178529A (ja) 2015-10-08
ZA201109444B (en) 2016-09-28
US9895436B2 (en) 2018-02-20
MX2011012347A (es) 2012-02-21
US8617564B2 (en) 2013-12-31
CN106924728A (zh) 2017-07-07
CN102458463A (zh) 2012-05-16
EP2432504B1 (en) 2019-05-01
SG176207A1 (en) 2011-12-29
WO2010135749A1 (en) 2010-11-25
KR20120087805A (ko) 2012-08-07
WO2010135749A9 (en) 2011-07-21
KR101746872B1 (ko) 2017-06-14
JP2012527486A (ja) 2012-11-08
US20100330112A1 (en) 2010-12-30
AU2010249330A1 (en) 2012-01-19
US20140227307A1 (en) 2014-08-14
US10653771B2 (en) 2020-05-19
BRPI1012811A2 (pt) 2016-03-29
ES2732815T3 (es) 2019-11-26
IL216508A0 (en) 2012-02-29
CA2797937C (en) 2020-01-14
RU2011147153A (ru) 2013-06-27
MY159500A (en) 2017-01-13
US20180369365A1 (en) 2018-12-27
CN106924728B (zh) 2021-02-05
JP6096839B2 (ja) 2017-03-15
NZ597182A (en) 2014-07-25
WO2010135747A1 (en) 2010-11-25
EP3590533A1 (en) 2020-01-08
IL216508A (en) 2016-08-31
CA2797937A1 (en) 2010-11-25
RU2585961C2 (ru) 2016-06-10
RU2585961C9 (ru) 2016-12-27
AU2010249330B2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
CN102458463B (zh) 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
US10350288B2 (en) Methods and compositions for treating herpes
US9782474B2 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9624273B2 (en) Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: D.Long

Inventor after: Flechtner Jessica

Inventor after: Skoberne Mojca

Inventor after: G - R - Siberia

Inventor before: D.Long

Inventor before: Flechtner Jessica

Inventor before: Skoberne Mojca

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: LONG DEBORAH FLECHTNER JESSICA SKOBERNE MOJCA TO: LONG DEBORAH FLECHTNER JESSICA SKOBERNE MOJCA SIBER GEORGE R.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170118

CF01 Termination of patent right due to non-payment of annual fee